Easily Accessible Adult Stem Cells: from Bench to Patient and Vice Versa

Lead Guest Editor: Manuel Scimeca Guest Editors: Rita Bonfiglio and Carrie-Ellen Briere



Easily Accessible Adult Stem Cells: from Bench to Patient and Vice Versa

Easily Accessible Adult Stem Cells: from Bench to Patient and Vice Versa

Lead Guest Editor: Manuel Scimeca Guest Editors: Rita Bonfiglio and Carrie-Ellen Briere

Copyright © 2021 Hindawi Limited. All rights reserved.

This is a special issue published in "Stem Cells International." All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chief Editor

Renke Li 🝺, Canada

Associate Editors

James Adjaye (D), Germany Andrzej Lange, Poland Tao-Sheng Li (D), Japan Heinrich Sauer (D), Germany Holm Zaehres (D), Germany

Academic Editors

Cinzia Allegrucci (D, United Kingdom Eckhard U Alt, USA Francesco Angelini (D), Italy James A. Ankrum (D, USA) Stefan Arnhold (D, Germany Marta Baiocchi, Italy Julie Bejoy 🕞, USA Philippe Bourin (D, France Benedetta Bussolati, Italy Leonora Buzanska (D, Poland Stefania Cantore D, Italy Simona Ceccarelli (D, Italy Alain Chapel (D), France Sumanta Chatterjee, USA Isotta Chimenti (D, Italy Mahmood S. Choudhery (D, Pakistan Pier Paolo Claudio (D, USA) Gerald A. Colvin (D, USA) Joery De Kock, Belgium Valdo Jose Dias Da Silva (D, Brazil Leonard M. Eisenberg (D, USA) Alessandro Faroni 🕞, United Kingdom Ji-Dong Fu D, USA Marialucia Gallorini (D, Italy Jacob H. Hanna 🕞, Israel David A. Hart (D, Canada Zhao Huang (D, China Elena A. Jones (D), United Kingdom Oswaldo Keith Okamoto (D, Brazil Alexander Kleger (D, Germany Laura Lasagni (D, Italy Shinn-Zong Lin (D, Taiwan Zhao-Jun Liu 🕞, USA Valeria Lucchino, Italy Risheng Ma, USA Giuseppe Mandraffino (D, Italy

Katia Mareschi (D), Italy Pasquale Marrazzo (D), Italy Francesca Megiorni 🕞, Italy Susanna Miettinen D, Finland Claudia Montero-Menei, France Christian Morsczeck, Germany Patricia Murray (D), United Kingdom Federico Mussano (D), Italy Mustapha Najimi (D, Belgium) Norimasa Nakamura (D, Japan Karim Navernia, United Kingdom Toru Ogasawara (D, Japan Paulo J Palma Palma, Portugal Zhaoji Pan 🝺, China Gianpaolo Papaccio, Italy Kishore B. S. Pasumarthi (D, Canada Manash Paul (D), USA Yuriy Petrenko (D), Czech Republic Phuc Van Pham, Vietnam Alessandra Pisciotta (D), Italy Bruno P#ault, USA Liren Qian (D, China Md Shaifur Rahman, Bangladesh Pranela Rameshwar (D, USA) Syed Shadab Raza Raza (D), India Alessandro Rosa (D, Italy Subhadeep Roy (D, India Antonio Salgado 🝺, Portugal Fermin Sanchez-Guijo (D, Spain Arif Siddiqui 🕞, Saudi Arabia Shimon Slavin, Israel Sieghart Sopper (D, Austria Valeria Sorrenti D, Italy Ann Steele, USA Alexander Storch (D), Germany Hirotaka Suga 🝺, Japan Gareth Sullivan (D, Norway Masatoshi Suzuki 🕞, USA Daniele Torella (D, Italy H M Arif Ullah (D, USA) Aijun Wang 🝺, USA Darius Widera (D, United Kingdom Wasco Wruck (D), Germany Takao Yasuhara, Japan Zhaohui Ye 🕞, USA

Shuiqiao Yuan (), China Dunfang Zhang (), China Ludovic Zimmerlin, USA Ewa K. Zuba-Surma (), Poland

Contents

The Therapeutic Potential of Inflamed Gingiva-Derived Mesenchymal Stem Cells in Preclinical Studies: A Scoping Review of a Unique Biomedical Waste Gamilah Al-Qadhi (1), Sarah Al-Rai (1), and Layla Hafed (1) Review Article (14 pages), Article ID 6619170, Volume 2021 (2021)



Review Article

The Therapeutic Potential of Inflamed Gingiva-Derived Mesenchymal Stem Cells in Preclinical Studies: A Scoping Review of a Unique Biomedical Waste

Gamilah Al-Qadhi^(b),¹ Sarah Al-Rai^(b),² and Layla Hafed^(b)

¹Department of Basic Dental Sciences, Faculty of Dentistry, University of Science and Technology, Yemen ²Department of Conservative and Preventive Dentistry, Faculty of Dentistry, Saba University, Yemen ³Department of Oral Pathology, Faculty of Oral and Dental Medicine, Ahram Canadian University, Giza, Egypt

Correspondence should be addressed to Gamilah Al-Qadhi; gamilah.alqadhi@dentistry.cu.edu.eg

Received 8 November 2020; Revised 8 January 2021; Accepted 27 January 2021; Published 10 February 2021

Academic Editor: Manuel Scimeca

Copyright © 2021 Gamilah Al-Qadhi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Searching for considerable abundance, simple, and accessible sources in stem cell-based therapy opens the door for isolation of a new population of oral/dental stem cells known as inflamed gingiva-derived mesenchymal stem cells, which have recently come to light with promising therapeutic potential in tissue regenerative therapy. Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines, this scoping review is aimed at highlighting the possible therapeutic potential of inflamed gingiva-derived mesenchymal stem cells in preclinical studies carried out to date and presenting the current evidence depends upon their comparison to the healthy gingiva-derived mesenchymal stem cells or other mesenchymal stem cell sources. A comprehensive electronic search using (PubMed, Embase, Scopus, and Web of Science) databases and a manual search of relevant references were conducted until June 2020. Included studies were assessed using a combination tool, including the guidelines for reporting preclinical *in vitro* studies on dental materials, which were based on the modification of the Consolidated Standards of Reporting Trial checklist and the guidelines for animal research: reporting of *in vivo* experiments. The initial research provided 360 articles, with 13 articles that met the inclusion criteria. While most of the included studies lacked randomization, blinding, and sample size calculation, they were designed accurately in other aspects of the guidelines. The results of this scoping review indicated that inflamed gingiva-derived mesenchymal stem cells could be effective in terms of osteogenic differentiation, collagen fiber formation, immunoregulation, migration capacity, and testing of dental material and may present a reliable alternative source for healthy gingiva-derived mesenchymal stem cells.

1. Introduction

Stem cell-based therapy has attracted many researchers in the regenerative medicine field, primarily mesenchymal stem cells (MSCs), which play a fundamental role with the surrounding microenvironment during the regenerative process [1]. Bone marrow and adipose tissues are the most commonly used sources. However, the associated invasive surgical procedure for both patient and donor opens the door to look for easily accessible and less invasive alternative sources. The discovery of prevalent cells having the typical characteristics of MSCs in the oral cavity has made scientists become

more interested in oral tissues. Oral-derived mesenchymal stem cells can be easily isolated from diverse sources, including dental pulp of permanent teeth or exfoliated deciduous teeth, periodontal ligaments, dental follicle, apical papilla, and alveolar bone. These cells displayed great plasticity towards trilineages, particularly towards the osteogenic lineage [2].

Moreover, gingival mesenchymal stem cells (GMSCs) are one of these doors denoting the recent newly identified population from dental/oral tissue. In several studies, mesenchymal stem cells isolated successfully from gingiva and met the minimal criteria proposed by the International Society for Cellular Therapy (ISCT) for MSCs' characterization. Human GMSCs showed self-renewal capabilities via the formation of colony-forming units (CFU), trilineage differentiation ability into osteoblast, adipocyte, and chondrocyte cell lineage under *in vitro* culture condition and expression of MSC markers and stem cell-specific genes [3–5].

Interestingly, the discarded diseased gingival tissue might represent a possible valid alternative source to healthy ones. Mesenchymal stem cell-like population obtained from inflamed gingival tissue had similar functional properties to the GMSCs isolated from healthy tissue. The trilineage differentiation capacity and surface marker expression were similar in both populations. Additionally, ectopic transplantation of stem cells from both sources resulted in the formation of a connective tissue-like structure similar to natural gingiva. However, the doubling time was declined in GMSCs derived from inflamed tissue [6, 7].

Likewise, other MSCs of inflamed dental origin were successfully isolated and characterized, and the MSCs isolated from inflamed gingiva and dental pulp tissues displayed a higher proliferation rate than the healthy control. Particularly, proinflammatory cytokines such as interleukin-1 β (IL-1 β) and tumor necrosis factor- α (TNF- α) promoted the expansion of both sources in vitro culture. The osteogenic markers were significantly higher in proinflammatory cytokine-treated dental pulp or gingival tissue in comparison to their untreated healthy ones. Clearly, the inflammatory environment did not change MSC markers or numbers neither osteogenic differentiation [8]. Further, the differentiation capacity of GMSCs and periodontal ligament mesenchymal stem cells (PDLSCs), whether derived from healthy or diseased periodontal ligament tissues, was similar [9].

On the contrary, another study stated that MSCs derived from inflamed periodontal ligament exhibited impaired immunomodulatory function and immune response via inhibition of T cell proliferation along with enhancement of osteoclastogenesis and alveolar bone loss in periodontitis, while cells obtained from healthy tissues showed the normal profile [10].

Furthermore, when GMSCs and PDLSCs were cultured in an osteogenic induction medium supplemented with TNF- α and IL-1 β to create an inflammatory microenvironment, both cells displayed a decline in the formation of mineralized nodules, alkaline phosphatase (ALP) activity, and expression of the following osteogenic markers: osteocalcin (OCN), runt-related transcription factor 2 (RUNX2), and collagen type 1 (COL1) [11].

Recently, GMSCs from healthy and inflamed tissue were loaded on microperforated membranes to evaluate their proliferation and migration capacity. The finding revealed that both sources are functionally and phenotypically characterized as MSCs. Notably, the proliferation rate was significantly higher in inflamed GMSCs. Concerning the migration dynamics, GMSCs whether from healthy or inflamed tissues exhibited a similar migration pattern toward chemoattractant through smaller pore sizes. It is worth noting that a better migratory activity was reported in GMSCs derived from healthy tissues in the case of large pore-sized membrane [12].

Similarly, the type of scaffold could play a critical role in cell growth and lineage direction. For example, GMSCs obtained from diseased tissue and seeded on two types of the scaffold, nano hydroxyapatite (HA) and collagen type 1, revealed that collagen type 1 scaffold supported growth and osteodifferentiation of GMSCs more than a nano HA [13]. In addition to the self-renewal, multipotent differentiation and migration capacity, which collectively represent one of the GMSC mechanisms in the regenerative approach, GMSCs have significant immunomodulatory and anti-inflammatory functions. The latter mechanism is mediated through suppression of inflammatory infiltrates and proinflammatory cytokines, induction of immunosuppressive factors such as IL-10, and increased infiltration of regulatory T cells [3]. Along with that, GMSCs promoted polarization of macrophages toward the anti-inflammatory M2 phenotype via increased expression of IL-10 and decreased expressions of IL-6 and TNF-*α* [14].

Additionally, Toll-like receptors (TLRs) may be responsible for cross talk between GMSCs and their inflammatory environment. Fawazy El-Sayed et al. [15] investigated the TLR expression profile of GMSCs in healthy and diseased conditions. The results showed that GMSCs cultured in basic medium expressed the following TLRs: 1, 2, 3, 4, 5, 6, 7, and 10, while those cultured in medium supplemented with inflammatory cytokines like IL-1 β , interferon- γ (IFN- γ), TNF- α , and IFN- α significantly expressed TLRs 1, 2, 4, 5, and 7 as well as 10 without TLR 6. This expression may determine the therapeutic potential of GMSCs in recognizing the pathway of pathogen-associated molecular patterns (PAMPs) in periodontal disease.

GMSCs regardless of their origin (healthy or inflamed gingival tissue) exhibited immunoregulatory functions, particularly immunosuppression, in a mouse skin allograft model through upregulation of putative systemic regulatory T cells (Tregs) [6]. On the contrary, MSCs derived from inflamed gingiva revealed impaired stemness and deficient immunomodulatory function. Fortunately, this deficiency could be rescued by pretreatment of inflamed GMSCs culture with acetylsalicylic acid (ASA), a type of nonsteroidal antiinflammatory drug (NSAID), which was able to increase the expression of Fas Ligand (FasL) and, in turn, induce T cell apoptosis [16]. Overall, the finding of I-GMSCs is a significant step in tissue regeneration as the existence of gingival tissue within a microenvironment characterized by constant bacterial challenges and inflammatory changes. In addition to that, their ability to resist these changes with maintaining their MSC's features opens the door for the possibility of using this source in the in vivo regenerative applications, where similar inflammatory factors are involved in a regenerative process [17].

The initial inflammation in the periodontal tissues is a physiologic rather than a pathological mechanism, and it is mainly characterized by plaque formation [18]. Although the oral rinses have antiplaque and antimicrobial actions against plaque accumulation [19], their effects on osteoblast precursors should be taken into consideration. In *in vitro* study, mouth rinses inhibited cell viability and changed the morphology of osteoblastic precursor cells regardless of their

type, duration, or alcohol content. However, this finding was limited and not sufficient to give evidence since it was confined to a laboratory environment, and further *in vivo* studies and clinical trials are required to assess the safety of oral rinse on various progenitor cells [20].

Inflammatory microenvironments that characterize different oral pathologies such as periodontitis and periapical cyst have shown that they are capable of modifying the characteristic of MSCs and even enhancing them in certain cases. For instance, MSCs obtained from human periapical cysts exhibited similar features to oral-/dental-derived MSCs such as high proliferative rate and extensive multipotency which makes them a potential source in regenerative medicine [21].

Stem cells isolated from the discarded gingival tissue have received much attention over recent years. The effectiveness of any intervention should be excessively examined in preclinical studies before translating into a clinical setting. To date, there was no available scoping review mapping the effectiveness of inflamed gingiva-derived mesenchymal stem cells in the tissue regenerative field. Therefore, the purpose of the current scoping review was to present what is known from the previous literature about the therapeutic role of inflamed GMSCs and certainly addressed the following question: To what extent would I-GMSCs be considered as an alternative approach for MSCs derived from healthy tissue in preclinical studies? The PICO relevant key elements were set as follows: population, in vitro cultures and animal studies; intervention, inflamed GMSCs; control or comparator, control: healthy GMSCs or other healthy MSC sources and/or comparator: other inflamed MSC sources; outcome, therapeutic potential.

2. Materials and Methods

The current scoping review was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines [22].

2.1. Protocol Registration. he protocol was registered with the Open Science Framework for scoping review protocol registration on 15 September 2020 at the following link: https://osf.io/jt62m and registration DOI: 10.17605/OSF.IO/JT62M.152.

2.2. Eligibility Criteria. The following articles, regardless of their outcome measures, were selected to be included in the current scoping review: (a) original experimental studies comparing GMSCs from the diseased tissue versus those isolated from healthy ones or those obtained from other MSC sources, (b) studies that treated GMSCs with proinflammatory cytokines in culture versus untreated cells, and (c) preclinical studies (*in vitro* or *in vivo*) and there was no language or date restrictions. On the other hand, nonexperimental articles such as reviews, case reports, and expert opinions were excluded during the first phase of screening. Further, studies using derivatives of inflamed GMSCs, such as exosomes or microvesicles, and studies that applied genetic modification were excluded during the second phase of screening. The materials and methods section should con-

tain sufficient detail so that all procedures can be repeated. It may be divided into headed subsections if several methods are described.

2.3. Information Sources and Search Strategy. In June 2020, four electronic databases (PubMed, Embase, Scopus, and Web of Science) were searched without any date or language restrictions. Key terms such as inflamed gingiva OR diseased gingiva OR discarded gingiva OR hyperplastic gingiva derived mesenchymal stem cells OR inflammation-derived gingival stem cells were initially used and resulted in a few retrieved papers. Therefore, a combination of keywords and index term keywords was expanded to include the following items: inflammation OR inflamed OR diseased OR discarded OR hyperplastic AND gingival mesenchymal stem cell OR gingiva derived mesenchymal stem cell OR gingival tissuederived mesenchymal stem cells OR gingiva derived stromal cell OR multipotent gingival stromal cell OR multipotent gingiva progenitor cell OR gingiva stem cells AND animal model OR experimental animal OR laboratory animal OR in vivo study OR in vitro study OR in vitro OR in vitro technique OR cell culture technique OR cell culture method OR culture technique OR preclinical study. The search strategy for each database was documented, and the retrieved references were combined and saved in one Mendeley folder. Then, duplicate records were removed.

2.4. Selection of Sources of Evidence. The selection of studies was carried out independently through two phases by two authors (Al-Qadhi and Hafed). First, the title and abstract of retrieved papers were screened to identify potentially eligible papers. References that did not fulfill the inclusion criteria were excluded. Second, full-text articles were screened in detail to assess and decide which study was appropriate for inclusion. Any disagreement in study selection was resolved by discussion, and the third author (Al-Rai) asked for her opinion. Reasons for exclusion were identified and documented.

2.5. Data Charting Process and Data Items. All authors participated in the process of designing the initial table and determining the data items. Data from the relevant studies were charted into a predesigned table by one author (Al-Qadhi) and then checked by two authors (Hafed and Al-Rai). Similar to the previous step, any disagreement in data entry was resolved by discussion with team members. The following items were extracted: study ID (author and year of publication), characteristics of methodology (study design; *in vitro* or *in vivo*, source of stem cells, sample collection, experimental sets or groups, scaffold, or carrier if present), and results of the included studies (clonogenic ability, population doubling capacity, phenotypic profile, differentiation profile, outcome measures, method of investigation, and endpoint).

2.6. Critical Appraisal of Individual Sources of Evidence. The quality assessment of included studies was carried out independently by (Al-Qadhi and Al-Rai). It should be noted that there is not a defined grading quality scale for preclinical studies, particularly *in vitro* studies. The experimental design

of all included studies was *in vitro* or *in vitro* followed by *in vivo* (ectopic confirmation). Therefore, guidelines for reporting preclinical *in vitro* studies on dental materials, which based on the modification of the Consolidated Standards of Reporting Trial (CONSORT) checklist [23], and the guidelines for Animal Research: Reporting of In Vivo Experiments (ARRIVE) were applied with some modification for quality assessment of included studies [24].

The grading system had two forms of responses. The first form was as follows: clearly inadequate, possibly accurate, and clearly accurate responses, which were scored with (1), (2), and (3), respectively; the second form was yes or no, which were scored with (0) and (1). The rating of overall quality was as follows: 1-9: low, 10-19: moderate, and 20-29: high for *in vitro* studies and 1-12: low, 13-24: moderate, and 25-38: high for *in vitro* followed by *in vivo* studies.

2.7. Synthesis of Results. The findings of the current research were summarized and presented in a tabular and textual qualitative manner. Meta-analysis was not applicable in the scoping review.

3. Results

3.1. Selection of Sources of Evidence. A total of 359 citations was identified from the defined electronic databases (PubMed = 181, Embase = 25, Scopus = 143, and Web of Science = 10), and one additional relevant article was detected through the manual search. After removing duplicate records, 260 papers were identified and subjected to the first level of screening (titles and abstracts) in which 240 irrelevant papers were excluded.

At the second level of screening (full texts), the remaining 20 articles were screened further and assessed for eligibility. Of these, seven articles were excluded as they did not meet the inclusion criteria. In detail, one study used stem cells from inflamed periodontal ligaments, not from the gingiva [9], one study did not use the inflamed gingival source (irrelevant intervention) [25], and one study used inflammatory cytokine-treated cells without untreated or healthy control groups [26]. Correspondingly, three studies used extracellular vesicles or external factors including microvesicles [27], epigenetic modification [28], and Retinol [29], as well as one study used stem cells obtained from healthy gingiva in an inflammatory animal model [30]. Thus, 13 studies were included in the current scoping review (Figure 1).

3.2. Characteristics of Sources of Evidence. The characteristics and the results of the included studies are reported in Tables 1 and 2, respectively. The included studies were published between 2011 and 2020. The experimental design of all studies was *in vitro* [6–8, 11–13, 15, 16, 31–35], and five of these were used *in vivo* models for further assessment [6, 7, 11, 16, 32]. All studies used the human as MSC source except one study used mice [16].

The majority of studies provided information about the diseased tissue sampling, while one article did not report the details [12]. MSCs from diseased gingiva were collected, whether directly during the gingivectomy procedure, extraction of periodontally affected teeth, and flap debridement [6–8, 13, 31, 32, 35] or indirectly via inflammatory preconditioned culture. In particular, GMSCs were treated with a culture containing inflammatory cytokines such as TNF- α , IL-1 β , IFN- γ , IFN- α , and IL-3 [11, 12, 15, 33], and an inflammatory animal model was created in one study, ligature-induced periodontitis in mice [16]. Regarding the healthy source, MSCs from healthy gingiva were obtained during the normal dental processes such as crown lengthening procedure and extraction of third molars due to impaction or orthodontic treatment.

In detail, five studies used H-GMSCs versus I-GMSCs [12, 13, 16, 31, 35], and two studies compared H-GMSCs with I-GMSCs as well as bone marrow mesenchymal stem cells (BMSCs) [6] or PDLSCs [7]. Further, two articles compared inflammatory cytokine-treated H-GMSCs with untreated ones [15, 33], and two studies compared inflammatory cytokine-treated H-GMSCs to untreated ones, as well as inflammatory cytokine-treated BMSCs and adipose-derived stem cells (ADSCs) [31], PDLSCs [11], and dental pulp stem cells (DPSCs) [8, 32].

The majority of studies performed several assessments regarding the characteristic of interventions, including clonogenic potential, proliferation rate, phenotypic profile, and functional differentiation (osteogenic, adipogenic, and chondrogenic [6, 7, 12, 16, 35], osteogenic and adipogenic [31, 32], and osteogenic [13]) for MSCs derived from both healthy and diseased gingival tissue. Three studies performed the characterization for MSCs derived from healthy tissue only [11, 15, 33], and one article did not conduct any MSC characterization assays [31] (Table 2).

A variety of outcomes in terms of the therapeutic potential of inflamed gingiva-derived MSCs was reported using appropriate methods of investigation. It should be noted that some studies have more than one outcome. These outcomes included osteogenic potential [8, 11, 13, 31–33], migration capacity [12, 34], formation of collagenous tissue [6, 7, 32], testing biocompatibility of resin composite [32], immuneregulation including TRL expressions [15], immunomodulation [6], and inflammatory receptor expression [31].

3.3. Critical Appraisal within Sources of Evidence. Overall, most of the included studies provided adequate information about abstract, background, objectives, the ethical approval, study design, experimental groups, result and its interpretation, outcome evaluation, statistical method, funding source, conflict of interest, and peer-review publication, following the items of the appropriate guideline. However, the majority of them lacked sample size calculation and provided incomplete details about replication, randomization, and blinding. All studies, with the exception of study conducted by Tomasello et al. [8], did not explain any excluded data, such as how many samples processed successfully or unsuccessfully due to bacterial contamination or other factors?. For *in vivo* part, none of the included studies stated the required information about 289 housing, husbandry conditions, the baseline characteristics, and the health status of animals. The quality of the in vitro and in vivo studies selected in this scoping review is shown in supplementary material I.




FIGURE 1: Flow diagram showing the different phases of literature screening for the scoping review process. (Editable file: PRISMA Flow Diagram, Liberati et al., 2009).

3.4. Results of Individual Sources of Evidence

3.4.1. Clonogenic, Proliferation, and Population Doubling Capacities. The clonogenic ability of I-GMSCs was higher than H-GMSCs in four studies [6, 8, 13, 31], lower in two studies [16, 33], and no significant difference between the two sources in three studies [7, 12, 32]. Likewise, the proliferation capacity of I-GMSCs was faster than H-GMSCs in four studies [7, 8, 13, 32] and lower in two studies [16, 33], and four articles reported that both I-GMSCs and H-GMSCs exhibited an increase in proliferation rate, somewhat similar to each other [6, 12, 31, 35]. It should be mentioned that two studies carried out the previous analysis for healthy tissue only [11, 15], and another two studies did not do this investigation at all [34, 35]. In the light of doubling population capacity, I-GMSCs were higher than H-GMSCs in four studies [6, 8, 12, 13] and shorter in two studies [7, 16]. The remaining studies did not conduct this assay (Table 2).

3.4.2. MSC Characterization. Concerning the specific features of MSCs, both I-GMSCs and H-GMSCs had typical MSCassociated surface markers, a similar positive expression for MSC markers STRO-1, CD29, CD44, CD90, CD105, and CD146 and negative for CD34 and CD45 in six studies [6, 7, 12, 32–34]. However, two studies reported higher expression of positive markers in diseased groups than healthy controls [8, 13], while one study stated the opposite [16]. Similarly, in five articles, both I-GMSCs and H-GMSCs had a similar trilineage differentiation capacity: osteogenic, chondrogenic, and adipogenic [6, 7, 12, 35] and osteogenic differentiation only [13]. Different capacity was reported in four articles, in which I-GMSCs showed lower osteogenic and adipogenic capacities [16, 32] and decline osteogenic potential [11], and H-GMSCs had higher osteogenicity, while I-GMSCs had a higher adipogenesis [33] (Table 2).

3.4.3. Main Findings of the Outcome. The following outcomes reported in the selected studies are as follows:

(1) Osteogenic Differentiation. Six of the included studies showed that I-GMSCs had potential osteogenic differentiation [8, 11, 13, 31–33]. More specifically, inflammatory cytokine-treated H-DPSCs and H-GMSCs as well as I-GMSCs were deeply stained and highly expressed osteogenic markers than untreated H-MSCs [8]. Although both cell sources had a tendency toward osteogenic differentiation, H-GMSCs had higher osteogenicity, while I-GMSCs showed increased adipogenesis [33]. Likewise, both sources showed a moderate expression of osteogenic markers (RUNX2, OCN, and osteopontin (OPN)) [13]. It is worth noting that the selective anti-inflammatory intervention could enhance osteogenic differentiation of GMSCs [35].

		Study	GMSC	Samp	le collection		perimental design	1	Scaffold or carrier
No.	Study ID	design	source	Healthy	Diseased	Source of interest	Other sources (if present)	Control	(if present)
1	Tang et al., 2011 [6]	In vitro & in vivo	Human	Not specified	Gingivectomy due to drug-induced gingival hyperplasia	I-GMSCs	-	H-GMSCs H-BMSCs (in vivo)	Subcutaneous transplantation of stem cells loaded on fibrin gel
2	Ge et al., 2012 [7]	In vitro & in vivo	Human	Crown lengthening procedure	Flap debridement in chronic periodontitis	I-GMSCs	-	H-GMSCS H-PDLSCs (in vivo)	Subcutaneous transplantation of stem cells mixed with HA/TCP powder
3	Li et al., 2013 [34]	<i>In vitro</i> & in vivo	Human	Not specified	Gingivectomy due to dental plaque- induced gingival hyperplasia (in vitro) Cells were treated with culture containing inflammatory cytokines TNF- α and IL-1 β (<i>in vivo</i>)	I-GMSCs (<i>in vitro</i>) Inflammatory cytokine- treated HGMSCs (<i>in vivo</i>)	Inflammatory cytokine- treated HDPSCs (<i>in vivo</i>)	H-GMSCs H-DPSCs	Subcutaneous transplantation of stem cell sheets
4	Yang et al., 2013 [11]	<i>In vitro</i> & in vivo	Human	Extraction of third molars	Cells were treated with culture containing inflammatory cytokines TNF- α and IL-1 β	Inflammatory cytokine- treated HGMSCs	Inflammatory cytokine- treated HPDLSCs	H-GMSCS H-PDLSCs	Subcutaneous transplantation of stem cell loaded on artificial bone repair materials (iliac Golden®)
5	Fawzy El-Sayed et al., 2016 [15]	In vitro	Human	Free gingival collar	Cells were treated with culture containing inflammatory cytokines TNF- α , IL-1 β , IFN- γ , and IFN- α	Inflammatory cytokine- treated HGMSCs	-	H-GMSCS	Culture medium
6	Barhanpurkar- Naik et al., 2017 [31]	In vitro and in vivo	Human	Not specified	Cells treated with inflammatory cytokine IL-3	Inflammatory cytokine- treated H- GMSCs	Inflammatory cytokine- treated HBMSCs and H-ADSCs	H-GMSCs H-BMSCs H-ADSCs	Culture medium
7	Tomasello et al., 2017 [8]	In vitro	Human	Extraction of third molars for orthodontic reasons	Extraction of periodontally affected molar	I-GMSCs Inflammatory cytokine- treated IGMSCs*	I-DPSCs Inf. cytokine- treated HDPSCs (in some experiment)	H-GMSCS H-DPSCs	Culture medium
8	Zhang et al., 2017 [35]	In vitro	Human	Free gingival collar	Cells were treated with IL-1 β , TNF- α , and IFN- γ	Inflammatory cytokine- treated H- GMSCs	Anti- inflammatory cytokine- treated H- GMSCs	H-GMSCs	Culture medium
9	Jauregui et al., 2018 [33]	In vitro	Human	Extraction of impacted third molars	Flap and osseous surgery in chronic periodontitis	I-GMSCs	_	H-GMSCs	Cells were seeded on electrospun polycaprolactone scaffolds

TABLE 1: Characteristics and methodologies of included studie	es.
---	-----

No.	Study ID	Study design	GMSC source	Samp Healthy	le collection Diseased	Ex Source of interest	perimental desigr Other sources (if present)	n Control	Scaffold or carrier (if present)
10	Soanca et al., 2018 [32]	In vitro	Human	Teeth extracted for orthodontic reasons	Gingival associated with overhanging posterior restoration	I-GMSCs	_	H-GMSCs	Culture medium
11	Yu et al., 2019 [16]	In vitro & in vivo	Mice	Gingival tissue from maxillary region	Ligature-induced periodontitis in mice	I-GMSCs	_	H-GMSCs	Systematic transplantation of stem cells (tail vein) into dextran sulfate sodium-induced mouse colitis
12	Al-Bahrawy et al., 2020 [12]	In vitro	Human	NS Author reported that discarded gingival sample from healthy gingiva	NS Author reported that discarded gingival sample from inflamed gingiva	I-GMSCs	-	H-GMSCs	Cells were seeded on perforated collagen-coated poly-tetra-floro- ethylene (PTFE) membrane
13	Cristaldi et al., 2020 [13]	In vitro	Human	Teeth extracted for orthodontic reasons	Extraction of periodontally affected teeth	I-GMSCs	_	H-GMSCs	Cells were seeded on Fisiograft Bone Granular® and Matriderm® scaffolds

TABLE 1: Continued.

Despite the fact that I-GMSCs showed a decline in the osteogenic differentiation [11, 32], particularly after treatment with inflammatory cytokines [34], GMSCs had more resistance to inflammation-related changes in terms of osteogenic potential *in vitro* and bone formation *in vivo* compared to PDLSCs [11].

(2) Formation of Collagenous Tissue. Three of the included articles confirmed that the I-GMSCs formed a dense connective tissue similar to normal gingiva. Both inflamed and non-inflamed sources generated dense collagenous connective tissue [6, 7, 32]. In particular, type 1 collagen [6, 32] and expression of intrinsic cytokines as matrix metallopeptidase-1 and -2 (MMP-1 and -2), IL-1, IL-6, and TNF- α were more evident in I-GMSCs [34].

(3) Immunoregulation. Concerning the immunoregulation, two studies demonstrated this function. Both GMSC sources (inflamed and healthy) showed distinct immunoregulatory functions in the allograft mouse model through elevation of Tregs with comparison to BMSCs [6]. H-GMSCs expressed TLRs 1, 2, 3, 4, 5, 6, 7, and 10, while GMSCs treated with inflammatory cytokines significantly expressed TLRs 1, 2, 4, 5, 7, and 10 without TLR 6 [15].

(4) Migration Capacity. Two of the selected studies reported that I-GMSCs migrated efficiently. No significant difference was observed between I-GMSCs and H-GMSCs, considering that IL-3 enhanced migration, motility, and wound closure; yet, BMSCs and ADSCs showed a higher expression of IL- $3R\alpha$ than GMSCs [31]. Notably, H-GMSCs migrated better than I-GMSCs through large-pore membrane [12].

(5) Testing Biocompatibility of Resin Composite. The study by Soancă et al. [32] is the only study that assessed the behaviour of I-GMSCs in relation to some commercial resin dental composite. This study suggested that I-GMSCs can be used as a useful and valued cell line for testing dental materials (Table 2 and Figure 2).

3.5. Synthesis of Results. Since the current scoping review included outcome measures that vary considerably, we focused on describing the included studies qualitatively in terms of their results rather than meta-analysis.

4. Discussion

The purpose of the current study was to review the potential therapeutic role of inflamed gingiva-derived mesenchymal stem cells in preclinical studies and highlight their role in comparison to healthy gingiva or other MSC sources. The preclinical experiment is the basic building block of any novel therapeutic approach. The majority of *in vitro* included studies fulfilled items related to the presenting and interpreting the data and used appropriate statistical analysis. However, the methodological quality assessment revealed a lack of important items like sample size calculation, randomization, blinding, and explanation of any excluded data.

It is thought these items can be applied for clinical and *in vivo* studies, and they are not practical for *in vitro* studies.

of Endpoint on	Both cells showed increasea'T cellratio of regulatory T cellsmodel(Tregs) in comparison tol and E)BMSCsBoth cells generatedhemicalcollagenous connective tissuewith type 1 collagen was moreevident in I-GMSCs	Both GMSCs generated dense hemical collagen tissue, while mineralized tissues observed only in PDLSCs	I-GMSCs exhibited lower adipogenic and osteogenic differentiation than H- XT-PCR GMSCs and osteogenic markers were heavily declined after treatment with cytokines	Inflammatory cytokine- treated GMSCs and DPSCs induced profibrotic f and E) phenotype. I-GMSCs had a higher expression of intrinsic cytokines (MMP)-1, MMP-2, IL-1, IL-6, TNF-α, and type 1 collagen than H-GMSCs	B	Inflammatory cytokine- treated cells showed decrease in bone formation capacity in comparison to the untreated ng) ones, higher osteogenic area in inf. cytokine-treated
Method of investigation	Coculture with T cell allogenic skin model Histological (H and E) and immunohistochemical analysis	Immunohistochemical analysis	Alzarin Red staining, ALP staining, RT-PCR	Histological (H and E) RT-PCR	Alizarin Red staining, ALP staining, and RT- qPCR/expression of osteogenic markers (OCN, RUNX2, and COL1)	Histological (H and E, MT staining)
Outcome measures	Immunoregulation/ immunosuppressive Formation of collagenous tissue	Formation of collagenous and mineralized tissues	Osteogenic potential	Formation of collagenous tissue	Osteogenic potential	Formation of bone
Trilineage differentiation	No significant difference (3 out 3) (osteo-adipo- chond)	Similar capacity (3 out 3)	Different capacity	(2 out 3) osteo +adipo (lower in I-GMSCs)	Compare between healthy	groups (H- GMSCs and H- PDLSCs)
Phenotypic profile	Similar expression/positive: STRO-1, CD29, CD44, CD90, CD105,CD146; negative: CD34, CD45	Similar expression/positive: CD44, CD73, CD90, CD105, CD166; negative: CD14, CD34, CD45	Similar expression/positive:	CD29, CD90, CD44, CD105, STRO-1, CD146; negative: CD34, CD45	Compare between	nearuny groups (rr- GMSCs and H- PDLSCs)
Population doubling capacity	I-GMSCs>H- GMSCs>BMSCs	H-GMSCs>I- GMSCs		Not reported*	Compare between healthy	groups (H- GMSCs and H- PDLSCs)
Proliferation rate	Both sources proliferated similar to each other and faster than BMSCs	I-GMSCs>H- GMSCs		I-GMSCs>H- GMSCs	Compare between healthy	groups (H- GMSCs and H- PDLSCs)
Clonogenic potential	I- GMSC3>H- GMSC3	No significant difference	;	No significant difference	Compare between	neauny groups (H- GMSCs and H-PDLSCs)
Study ID	Tang et al., 2011 [6]	Ge et al., 2012 [7]		Li et al., 2013 [34]	Lo 45	1 ang et al., 2013 [11]
No.	-	2		σ		4

TABLE 2: Results of included studies.

Phenotypic profileTrilineageOutcome measures# done for H-GMSCs (3 outTRL expression# done for H-GMSCs (3 outTRL expression# done for H-GMSCs (3 outTRL expression# done for H-MSCs, butND# expression/positive:NDSight differentND# done for H-GMSCs (3 outOsteogenic potential# done for H-GMSCs3) (osteo-adipo-# done for H-GMSCs (3 out of 3) H-expression/positive:CD34, CD45, HLA-DRND# done for H-GMSCs (3 out of 3) H-expression/positive:CD34, CD45, HLA-DR# done for H-GMSCs (3 out of 3) H-expression/positive:CD34, CD45, HLA-DRfor of 3) H-Costeo-adipo-for of 3) H-Costeo-						TABLE 2. COILUITUCU	ommen.			
# done for # done for H-GMSCsW done for # done for H-GMSCsHGMSCs (3 out and word)TRL expression profileNDNDNDND# done for H-GMSCsII3Na expression profileNDNDNDNDR done for H-MSCs, but data not presentedNDII3Na expression profileSignificant difference CMSCs-H- DSSCS-H- DSSC	÷	Study ID	Clonogenic potential	Proliferation rate	Population doubling capacity	Phenotypic profile	Trilineage differentiation	Outcome measures	Method of investigation	Endpoint
ND ND ND ND RR ND Profile ND ND ND ND MD Profile Profile Significant Ana not presented ND # done for H-MSCs, but ND Profile Significant EGMSCs-H CMSCs and H # done for H-MSCs, but ND Profile DPSCs-HL CMSCs-H CMSCs and H CMSCs and H Profile Profile DPSCs-HL CMSCs and H CMSCs and H CMSCs and H Profile Profile DPSCs-HL CMSCs and H CMSCs and H CMSCs and H Profile Profile Significant CMSCs and H CMSCs and H Profile Profile Profile CMSCs and H CMSCs and H CMSCs and A Significant Profile Profile CMSCs and H CMSCs and A Significant Profile Profile Profile CMSCs and anti- CMSCs and anti- Profile Profile Profile Profile CMSCsi-I MO		Fawzy El- Sayed et al. 2016 [15]	# done for H-GMSCs	# done for HGMSCs	QN	# done for H-GMSCs	#done for HGMSCs (3 out 3) (osteo-adipo- chond)	TRL expression profile	Flow cytometry, mRNA expression	H-GMSCs expressed TLRs 1, 2, 3, 4, 5, 6, 7, and 10, while inf. cytokine-treated GMSCs expressed TLRs 1, 2, 4, 5, and 7 as well as 10 without TLR 6
Significant difference 1-GMSCs and I- GMSCs and I- BPSCs		Barhanpurkar –Naik et al., 2017 [31]	ND	QN	QN	NR # done for H-MSCs, but	QN	IL-3Ra expression profile	Flow cytometry, mRNA expression	The mRNA expression of 3 sources was similar; however, the protein expression was different (BMSCs and ADSCs showed higher expression of IL-3Rø than GTMSCs)
Significant difference I-GMSGsI-GMSGs GMSGs>H- GMSGs>H- DPSCs>H- DPSCs and H- GMSCs and day) H- GMSCs and day) H- anti- GMSCs and anti- IGMSCs and anti- IGMSCs and anti- IGMSCs and anti- IGMSCs A M- GMSCs>I- time point 12 MSC MSCS GMSCs and anti- IGMSCs A MSCSI- I- GMSCs GMSC A MODND Steogenic potential Significant poliferation rate (GMSCs)- modeND I- A done for H-GMSC A (Steogenic potential (Steogenic potential (Migration, motility, and wound healing capacity	In vitro cell migration, motility, and wound healing assays	No significant differences in all three sources, IL-3 enhanced migration, motility, and wound closure.
Various SignificantVarious proliferation rate differenceVarious according to H-Various mtionH-duration*; (last duration*; (last GMSCs>I- GMSCs and anti- GMSCs and GMSCsND# done for HGMSCs (3 out (3) (osteo-adipo- chond)GMSCs>I-time point 12 dMSCs and anti- GMSCs and anti- IGMSCsND# done for H-GMSCs (3) (osteo-adipo- chond)GMSCs>I-GMSCs>I-IGMSCs anti- GMSCsSimilar (2 out of 3) H- GMSCs higher chond)H-exhibited morease in proliferation rateNDSimilar expression/positive: GMSCs CD19, ADB Different capacity osteogenicity, Mile I-GMSCs		Tomasello et al., 2017 [8]	Significant difference I-GMSCs and I- DPSCs>H- GMSCs and H-DPSCs	I-DPSCs and I- GMSCs>H- DPSCs and H- GMSCs	I- GMSCs and I- DPSCs>H- GMSCs and H- DPSCs	Slight different expression/positive: STRO-1, CD146, CD29, SSEA4 (higher expressed in diseased groups); negative: CD34, CD45, HLA-DR	QN	Osteogenic potential	Alizarin Red staining and RT- aPCR/expression of osteogenic markers (RUNX2, OPN, and OCN)	Inflammatory cytokine- treated H-DPSCs and H- GMSCs as well as I-MSCs were deeply stained and highly expressed osteogenic markers than untreated H- MSCs.
H- Both sources Similar (2 out of 3) H- GMSCs>L- exhibited ND CD105, CD73, CD90; higher Osteogenic potential increase in CD45, CD134, osteogenicity, Osteogenic potential proliferation rate CD45, CD11b, HLA- while I-GMSCs DA850 proliferation rate DB850 DB44 osteogenicity, DB4000000000000000000000000000000000000		Zhang et al., 2017 [35]	Significant difference H- GMSCs>l- GMSCs and anti- IGMSCs	Various proliferation rate according to duration*; (last time point 12 day) H- GMSCs>I- GMSCs and anti- IGMSCs	Q	# done for H-GMSCs	#done for HGMSCs (3 out 3) (osteo-adipo- chond)	Osteogenic potential	Alizarin Red staining and RT- aPCR/expression of osteogenic markers (RUNX2, ALP, COL1, and OPN)	The number of calcified nodules as well as expression of osteogenic factors were higher in the anti- inflammatory group than in the control group and in the inflammatory group
		Jauregui et al., 2018 [33]	H- GMSCs>I- GMSCs	Both sources exhibited increase in proliferation rate	QN	Similar expression/positive: CD105, CD73, CD90; negative: CD19, CD34, CD45, CD11b, HLA- DR	Different capacity (2 out of 3) H- GMSCs had higher osteogenicity, while I-GMSCs showed increased adipogenesis	Osteogenic potential	Alizarin Red staining and ALP activity	Both cell sources had a tendency toward osteogenic differentiation.

Endpoint	I-GMSCs can be used as valuable cell line for testing dental material	I-GMSCs showed impaired immunomodulatory properties, and this impairment was rescued when cells treated with acetylsalicylic acid.	No significant difference between I-GMSCs and H- GMSCs through small pores, while H-GMSCs migrated better than I-GMSCs through large-pore membrane	Cell growth or colonization on collagen scaffold was higher in I-GMSCs than H-GMSCs	Both GMSCs did not grow on nano HA, while they grew effectively on collagen scaffold compared to the unloaded cells/both cells showed a moderate expression of osteogenic markers (RUNX2, OCN, OPN)
Method of investigation	PKH26 cell membrane fluorescent labeling MTT assay	Coculture with T cells	Migration assay	Different cell viability assay	Alizarin Red staining and RT- qPCR/expression of osteogenic markers (RUNX2, OCN, and OPN)
Outcome measures	Testing biocompatibility of resin composite	Immunomodulation	Migration capacity	Cell growth	Osteogenic potential
Trilineage differentiation	Similar capacity with few cells expressed osteogenic markers (3 out 3 +neurogenic).	I-GMSCs showed decrease tridifferentiation potential	Similar capacity (3 out 3)		(1 out 3) osteogenic
Phenotypic profile	Similar expression/positive: CD105, CD73, CD90, CD49e, CD29, CD44, CD166; negative: CD14, CD34, CD45, CD79, CD117, HLA- DR	Different expression/positive: Sca1, CD105, CD90, CD73 (significantly decreased in IGMSCs); negative: CD45, CD34	Positive: CD105, CD73, CD90, CD164; negative: CD14, CD34, CD45	Slight different	CD73, CD29, CD90, CD105 (slightly increased expression of CD90 and CD105 in IGMSCs); negative: CD45, HLA-DR
Population doubling capacity	QN	H-GMSCs>I- GMSCs	I-GMSCS>H- GMSCs		I-GMSCS>H- GMSCs
Proliferation rate	Both sources exhibited Increase in proliferation rate	H-GMSCs>I- GMSCs	Both sources exhibited increase in proliferation rate		I-GMSCs>H- GMSCs
Clonogenic potential	ND	H- GMSCs>I- GMSCs	No significant differences		I- GMSCs>H- GMSCs
Study ID	Soanca et al., 2018 [32]	Yu et al., 2019[16]	Al- Bahrawy et al., 2020 [12]		Cristaldi et al., 2020 [13]
No.	10	11	12		13

TABLE 2: Continued.




FIGURE 2: Possible applications and therapeutic roles of inflamed gingiva-derived mesenchymal stem cells.

Since many simple procedures should be added to design *in vitro* studies in order to reduce the bias, a well-designed *in vitro* experiment will positively affect their outcome and, in turn, their translation to *in vivo* and clinical applications. Randomization is essential for *in vitro* experiments because it deals with various issues that do not always have the same environment. For this reason, a culture flask or dish can be assigned at random to intervention and a column of wells in a multiwell plate may all be allocated to the same group. Thus, the column is considered as a single experimental unit, and the statistical analysis should be performed on the whole data from the whole column rather than on data from individual wells [23, 36]. Additionally, selecting fields for capturing histological or radiographical pictures should be done at random as well.

Before data processing, it might be useful to use a sample coding to blind the treatment category. Moreover, sample size can be estimated using either power analysis or the resource equation method, and the latter one is suitable in the case of in vitro studies where the absence of ethical issue and somewhat inexpensive experimental units so the upper limit can be increased [36]. The analysis of in vivo studies revealed several issues similar to the *in vitro* studies, namely, sample size, randomization, and blinding. In addition to that, all studies did not have enough and sufficient information about housing and husbandry conditions of animals, baseline data (characteristic and health status of animals), and an explanation of any excluded data. Determination of sample size is one of the important steps in designing animal studies; a fewer number of animals may lead to missing of any significant difference, and more number of animals selected may lead to misuse of resources and ethical problems [37].

Also, the standardization process is required to accurately evaluate the behaviour of cells. Recently, an innovative

method using computer-aided design (CAD) technology was introduced to design a standardized sample culture plate model for *in vitro* studies to provide similar size and shape of scaffolds, to ensure optimum interaction between the seeded cells and these biomaterials and, in turn, to reduce bias in the measurements and results [38].

In respect of clonogenic, proliferation, and doubling population capacities, most of the selected studies indicate that there was no significant difference between I-GMSCs and H-GMSCs; even the inflamed group was higher than the healthy one indicating that the inflamed condition could positively affect the regeneration potential of GMSCs. It has to be mentioned that not all included studies performed the previous assay so we present the available finding. Equally important, the majority of articles show that both I-GMSCs and H-GMSCs display a positive expression of the principle MSC markers: STRO-1, CD29, CD44, CD90, CD105, and CD146 and negative expression of hematopoietic markers: CD34 and CD45. Both sources have the ability to differentiate into osteogenic, chondrogenic, and adipogenic lineage, while a minority of studies indicate that I-GMSCs have lower osteogenic and adipogenic differentiation capacity than the healthy groups. This finding is consistent with minimal criteria for MSCs proposed by the International Society for Cellular Therapy (ISCT) [39], so the resistance of GMSCs to inflammatory stimuli and maintaining their MSC features under inflammatory condition make them an attractive MSC source in tissue regenerative researches, where they could be subjected to similar inflammatory microenvironment [17].

Overall, the osteogenic potential and formation of collagenous tissues are confirmed by histological, immunohistochemical, and gene expressions. The most common methods used to evaluate the osteogenic potential of included

studies are Alizarin Red staining, Haematoxylin and Eosin (H&E) staining, and the expression of osteogenic markers (RUNX2, ALP, OCN, and OPN). The immunohistochemical analysis used to assess the collagenous tissue formation has been reported by the studies conducted by Tang et al. and Ge et al. [6, 7]. In one study, H-GMSCs had higher osteogenicity, while I-GMSCs showed increased adipogenesis and this is maybe accounted for the difference in epigenetic factors that are associated with chronic periodontitis and affect the differential directions of these cell lines [33]. Several included studies confirmed that osteoblastic differentiation capacity under proinflammatory treated culture was significantly higher than uninduced cultures and almost equal to periodontally affected MSCs. It has been known that proinflammatory mediators such as IL-1 β and TNF- α play a crucial role in activating intracellular pathways required in cellular viability, proliferation, and differentiation toward certain cell lines. For instance, TNF- α induces the osteogenic differentiation of DPSCs by activation of the NF- κ B pathway [31, 40].

Besides, the inflammatory microenvironment activates cytoskeletal remodeling via interaction between high levels of chaperone proteins like heat shock protein 90 (hsp90), thioredoxin-1 (TXN-1), and heat shock protein A9 (hspA9) and actin filaments like cofilin, profiling, and vinculin, leading to stabilize actin filaments, and this interaction is closely related to the differentiation process [8]. Although the existence of an inflammatory state led to a decrease in the osteogenic differentiation in some studies [11, 32], GMSCs exhibited more resistance to inflammation-related changes compared to PDLSCs [11].

PDLSCs, on the other hand, have limited cell availability and reduced therapeutic viability, whereas gingival tissue is relatively abundant and easily accessible. Further, both MSCs from inflamed and noninflamed gingival tissues generated dense collagenous connective tissue resembles the natural gingiva [6, 7, 32], with type 1 collagen [6, 32], and expression of intrinsic cytokines MMP-1, MMP-2, IL-1, IL-6, and TNF- α were more evident in I-GMSCs [34]. Cross talk between GMSCs, extracellular matrix, inflammatory mediators, and inflammatory cells induce the profibrotic phenotype of cells.

A class of sensor proteins known as TLRs mediates recognition of PAMPs and initiation of inflammation as well as immune responses. Microbial products stimulate TLRs and lead to the activation of signaling pathways that result in the induction of antimicrobial genes and inflammatory cytokines. In addition to their expression in immune cells (e.g., dendritic cells and macrophages) and nonimmune cells (e.g., fibroblast and epithelial cells), several TLRs are expressed in MSCs and contribute to the protection against infection. Based on MSC origin, an inflammatory condition may modulate the pattern and role of TLRs expressed by MSCs [41, 42]. Among these MSCs, I-GMSCs highly express TLRs 1, 2, 4, 5, 7, and 10, enhancing the capacity of G-MSCs to recognize *in vivo* periodontal PAMPs [15].

Notably, H-GMSCs have the ability to ameliorate inflammation in a colitis experimental model, and I-GMSCs improve subcutaneous transplantation of murine skin allografts via activation or generation of infiltrating regulatory T cells [3, 6]. These may be attributed to highly conserved cross-species effects of cytokines, mediating the immunoregulatory effects of MSC or maybe due to the production of IL-10 and indoleamine 2,3-dioxygenase (IDO), which mediate immunoregulation [3, 6].

The migration of MSCs toward the damaged tissue is an important step in tissue regeneration. Concerning the migration capacity in the healthy and inflamed groups, there was no significant difference in the number of migrated GMSCs across different membrane micropore sizes, except for large sizes, where H-GMSCs displayed a higher migratory dynamic. This finding is related to developing selective driven membranes for tissue regeneration, particularly for periodontal regeneration, which enable stem cells to migrate through the scaffold [12]. IL-3 significantly enhances the migration, motility, and wound healing abilities of MSCs, including I-GMSCs, by upregulating the expression of chemokine receptors (CXCR4). Moreover, IL-3-induced CXCR4 expression leads to increased migration of MSCs towards SDF-1 α , enhancing the migration and homing efficiency of MSCs [31].

Culture condition is one of the most essential factors in controlling MSC homing and migration efficiency: proinflammatory cytokines TGF- β 1, IL-1 β , and TNF- α facilitated BMSC migration across reconstituted human basement membranes by increasing production of MMP-2, MT1-MMP, and/or MMP-9 in these cells. This *in vitro* result provides a potential mechanism in MSC recruitment and migration toward the damaged tissue *in vivo* [43].

Lastly, I-GMSCs can be used as a useful and valued cell line for testing resin composite dental material due to the proximity of dental material to gingival tissue, and the standard cytotoxicity tests cannot predict *in vivo* behaviour of commercial materials. So, it is a good idea to determine the biocompatibility of dental materials at the cellular level using discarded human cell lines rather than animal lines [32].

5. Limitations

Included studies did not perform enough *in vitro* MSC characterization of cells derived from the inflamed tissue. Also, the lack of consistency between in vitro and subsequent *in vivo* study (ectopic formation) in the same article constituted another limitation in some studies.

6. Conclusion

The gingiva represents the easiest and most accessible MSC source in the oral cavity. Inflamed gingiva-derived MSCs are considered a unique biomedical waste as they retain their viability, morphology, phenotypic, and functional features of MSCs under inflammatory conditions. In addition to this, the inflammatory microenvironment promoted migration capacity and motility of GMSCs. Since the existence of an inflammatory microenvironment does not negatively affect MSC characterization, I-GMSCs could be used in experiments that involved diseases with persistent inflammatory conditions. In preclinical studies, I-GMSCs showed a colony formation ability similar or even more than healthy ones and a proliferation capacity faster than control groups. Besides, I-GMSCs could be a promising source in the following aspects: osteogenic differentiation, collagen fiber formation, immunoregulation, and testing of dental materials. Even though I-GMSCs represent a new therapeutic solution and could be a viable alternative source to H-GMSCs for tissue regeneration purposes, further and well-designed preclinical studies are required to confirm the previous findings and to determine the feasibility of this source. Equally important, the authors should follow the standard guideline as much as possible to reduce bias and gaps between preclinical searches and clinical use.

Abbreviations

ADSCs:	A dinaga dariwad stam calls
ADSCS: ALP:	Adipose-derived stem cells
	Alkaline phosphatase
ASA:	Acetylsalicylic acid
BMSCs:	Bone marrow mesenchymal stem cells
CFU:	Colony-forming units
COL1:	Collagen type 1
CXCR:	Chemokine receptor
DPSCs:	Dental pulp stem cells
FASL:	Fas Ligand
GMSCs:	Gingival mesenchymal stem cells
HA:	Hydroxyapatite
H-GMSCs:	Healthy gingiva-derived mesenchymal stem
	cells
hsp:	Heat shock protein
IDO:	Indoleamine 2,3-dioxygenase
IFN- <i>y</i> :	Interferon-y
I-GMSCs:	Inflamed gingiva-derived mesenchymal stem
	cells
IL-1 <i>β</i> :	Interleukin-1 β
ISCT:	International Society for Cellular Therapy
MMP:	Matrix metallopeptidase
MSCs:	Mesenchymal stem cells
NSAID:	Nonsteroidal anti-inflammatory drug
OCN:	Osteocalcin
OPN:	Osteopontin
PAMPs:	Pathogen-associated molecular patterns
PDLSCs:	Periodontal ligament mesenchymal stem cells
RUNX2:	Runt-related transcription factor 2
TLRs:	Toll-like receptors
TNF-α:	Tumor necrosis factor- α
Tregs:	Regulatory T cells
TXN-1:	Thioredoxin-1.
17710-1.	

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

Supplementary material I: the quality of the *in vitro* and *in vivo* studies selected in this scoping review. (Supplementary Materials)

References

[1] A. Ballini, S. Cantore, S. Scacco, D. Coletti, and M. Tatullo, "Mesenchymal stem cells as promoters, enhancers, and playmakers of the translational regenerative medicine 2018," *Stem Cells International*, vol. 2018, 2 pages, 2018.

- [2] G. Spagnuolo, B. Codispoti, M. Marrelli, C. Rengo, S. Rengo, and M. Tatullo, "Commitment of oral-derived stem cells in dental and maxillofacial applications," *Dental Journal*, vol. 6, no. 4, pp. 72–78, 2018.
- [3] Q. Zhang, S. Shi, Y. Liu et al., "Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis," *Journal of Immunology*, vol. 183, no. 12, pp. 7787–7798, 2009.
- [4] B. P. J. Fournier, F. C. Ferre, L. Couty et al., "Multipotent progenitor cells in gingival connective tissue," *Tissue Engineering Part A*, vol. 16, no. 9, pp. 2891–2899, 2010.
- [5] N. Mensing, H. Gasse, N. Hambruch, J. D. Haeger, C. Pfarrer, and C. Staszyk, "Isolation and characterization of multipotent mesenchymal stromal cells from the gingiva and the periodontal ligament of the horse," *BMC Veterinary Research*, vol. 7, no. 1, p. 42, 2011.
- [6] L. Tang, N. Li, H. Xie, and Y. Jin, "Characterization of mesenchymal stem cells from human normal and hyperplastic gingiva," *Journal of Cellular Physiology*, vol. 226, no. 3, pp. 832–842, 2011.
- [7] S. Ge, K. M. Mrozik, D. Menicanin, S. Gronthos, and P. M. Bartold, "Isolation and characterization of mesenchymal stem cell-like cells from healthy and inflamed gingival tissue: potential use for clinical therapy," *Regenerative Medicine*, vol. 7, no. 6, pp. 819–832, 2012.
- [8] L. Tomasello, R. Mauceri, A. Coppola et al., "Mesenchymal stem cells derived from inflamed dental pulpal and gingival tissue: a potential application for bone formation," *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 179, 2017.
- [9] S. Santamaría, N. Sanchez, M. Sanz, and J. A. Garcia-Sanz, "Comparison of periodontal ligament and gingiva-derived mesenchymal stem cells for regenerative therapies," *Clinical Oral Investigations*, vol. 21, no. 4, pp. 1095–1102, 2017.
- [10] D. Liu, J. Xu, O. Liu et al., "Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation," *Journal of Clinical Periodontology*, vol. 39, no. 12, pp. 1174–1182, 2012.
- [11] H. Yang, L. Gao, Y. An et al., "Comparison of mesenchymal stem cells derived from gingival tissue and periodontal ligament in different incubation conditions," *Biomaterials*, vol. 34, no. 29, pp. 7033–7047, 2013.
- [12] M. Al Bahrawy, K. Ghaffar, A. Gamal, K. El-Sayed, and V. Iacono, "Effect of inflammation on gingival mesenchymal stem/progenitor cells' proliferation and migration through microperforated membranes: an in vitro study," *Stem Cells International*, vol. 2020, Article ID 5373418, 10 pages, 2020.
- [13] M. Cristaldi, R. Mauceri, G. Campisi et al., "Growth and osteogenic differentiation of discarded gingiva-derived mesenchymal stem cells on a commercial scaffold," *Frontiers in Cell and Development Biology*, vol. 8, 2020.
- [14] Q.-Z. Zhang, W.-R. Su, S.-H. Shi et al., "Human gingivaderived mesenchymal Stem Cells Elicit Polarization of M2 Macrophages and enhance cutaneous wound healing," *Stem Cells*, vol. 28, no. 10, pp. 1856–1868, 2010.
- [15] K. Fawzy-El-Sayed, M. Mekhemar, S. Adam-Klages, D. Kabelitz, and C. Dörfer, "TLR expression profile of human gingival margin-derived stem progenitor cells," *Medicina Oral, Patología Oral y Cirugía Bucal*, vol. 21, no. 1, pp. e30–e38, 2016.

- [16] T. Yu, B. Yan, J. Li et al., "Acetylsalicylic acid rescues the immunomodulation of inflamed gingiva-derived mesenchymal stem cells via upregulating FasL in mice," *Stem Cell Research & Therapy*, vol. 10, no. 1, p. 368, 2019.
- [17] K. M. Fawzy el-Sayed and C. Dörfer, "Gingival mesenchymal stem/progenitor cells: a unique tissue engineering gem," *Stem Cells International*, vol. 2016, 16 pages, 2016.
- [18] A. Cekici, A. Kantarci, H. Hasturk, and T. E. Van Dyke, "periodontal disease," *Periodontology 2000*, vol. 6, no. 3, pp. 165-166, 1961.
- [19] S. Cantore, A. Ballini, G. Mori et al., "Anti-plaque and antimicrobial efficiency of different oral rinses in a 3-day plaque accumulation model," *Journal of Biological Regulators and Homeostatic Agents*, vol. 30, no. 4, pp. 1173–1178, 2016.
- [20] I. S. Song, J. E. Lee, and J. B. Park, "The effects of various mouthwashes on osteoblast precursor cells," *Open Life Sciences*, vol. 14, no. 1, pp. 376–383, 2019.
- [21] M. Tatullo, B. Codispoti, A. Pacifici et al., "Potential use of human periapical cyst-mesenchymal stem cells (hPCy-MSCs) as a novel stem cell source for regenerative medicine applications," *Frontiers in Cell and Development Biology*, vol. 5, 2017.
- [22] A. C. Tricco, E. Lillie, W. Zarin et al., "PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation," *Annals of Internal Medicine*, vol. 169, no. 7, pp. 467–473, 2018.
- [23] C. M. Faggion, "Guidelines for reporting pre-clinical in vitro studies on dental materials," *The Journal of Evidence-Based Dental Practice*, vol. 12, no. 4, pp. 182–189, 2012.
- [24] C. Kilkenny, W. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman, "Animal research: Reportingin vivoExperiments—The ARRIVE guidelines," *Journal of Cerebral Blood Flow and Metabolism*, vol. 31, no. 4, pp. 991–993, 2011.
- [25] M. K. Mekhemar, S. Adam-Klages, D. Kabelitz, C. E. Dörfer, and K. M. Fawzy El-Sayed, "TLR-induced immunomodulatory cytokine expression by human gingival stem/progenitor cells," *Cellular Immunology*, vol. 326, pp. 60–67, 2018.
- [26] C. Giacomelli, L. Natali, M. Nisi et al., "Negative effects of a high tumour necrosis factor-α concentration on human gingival mesenchymal stem cell trophism: the use of natural compounds as modulatory agents," *Stem Cell Research & Therapy*, vol. 9, no. 1, p. 135, 2018.
- [27] R. Wang, Q. Ji, C. Meng et al., "Role of gingival mesenchymal stem cell exosomes in macrophage polarization under inflammatory conditions," *International Immunopharmacology*, vol. 81, article 106030, 2020.
- [28] Q. Li, F. Liu, R. Dang et al., "Epigenetic modifier trichostatin A enhanced osteogenic differentiation of mesenchymal stem cells by inhibiting NF-κB (p65) DNA binding and promoted periodontal repair in rats," *Journal of Cellular Physiology*, vol. 235, no. 12, pp. 9691–9701, 2020.
- [29] K. M. Fawzy el-Sayed, D. Hein, and C. Dörfer, "Retinol/inflammation affect stemness and differentiation potential of gingival stem/progenitor cells via Wnt/β-catenin," *Journal of Periodontal Research*, vol. 54, no. 4, pp. 413–423, 2019.
- [30] Y. Luo, W. Wu, J. Gu et al., "Human gingival tissue-derived MSC suppress osteoclastogenesis and bone erosion via CD39-adenosine signal pathway in autoimmune arthritis," *eBioMedicine*, vol. 43, pp. 620–631, 2019.
- [31] A. Barhanpurkar-Naik, S. T. Mhaske, S. T. Pote, K. Singh, and M. R. Wani, "Interleukin-3 enhances the migration of human mesenchymal stem cells by regulating expression of CXCR4," *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 168, 2017.

- [32] A. Soancă, M. Lupse, M. Moldovan et al., "Applications of inflammation-derived gingival stem cells for testing the biocompatibility of dental restorative biomaterials," *Annals of Anatomy*, vol. 218, pp. 28–39, 2018.
- [33] C. Jauregui, S. Yoganarasimha, and P. Madurantakam, "Mesenchymal stem cells derived from healthy and diseased human gingiva support osteogenesis on electrospun polycaprolactone scaffolds," *Bioengineering*, vol. 5, no. 1, p. 8, 2018.
- [34] N. Li, J. Zhou, L. Tang et al., "Inflammatory environment induces gingival tissue-specific mesenchymal stem cells to differentiate towards a pro-fibrotic phenotype," *Biology of the Cell*, vol. 105, no. 6, pp. 261–275, 2013.
- [35] F. Zhang, M. Si, H. Wang, M. K. Mekhemar, C. E. Dörfer, and K. M. Fawzy El-Sayed, "IL-1/TNF-α inflammatory and antiinflammatory synchronization affects gingival stem/progenitor cells' regenerative attributes," *Stem Cells International*, vol. 2017, 9 pages, 2017.
- [36] M. F. W. Festing, O. Box, and L. Road, "Guidelines for the design and statistical analysis of experiments in papers submitted to ATLA," *Alternatives to Laboratory Animals*, vol. 29, no. 4, pp. 427–446, 2001.
- [37] J. Charan and N. Kantharia, "How to calculate sample size in animal studies ?," *Journal of Pharmacology and Pharmacotherapeutics*, vol. 4, no. 4, pp. 303–306, 2013.
- [38] M. Marrelli, A. Pujia, F. Palmieri et al., "Innovative approach for the in vitro research on biomedical scaffolds designed and customized with CAD-CAM technology," *International Journal of Immunopathology and Pharmacology*, vol. 29, no. 4, pp. 778–783, 2016.
- [39] M. Dominici, K. le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," *Cytotherapy*, vol. 8, no. 4, pp. 315–317, 2006.
- [40] X. Feng, G. Feng, J. Xing et al., "TNF-α triggers osteogenic differentiation of human dental pulp stem cells via the NF-κB signalling pathway," *Cell Biology International*, vol. 37, no. 12, pp. 1267–1275, 2013.
- [41] M. Najar, M. Krayem, N. Meuleman, D. Bron, and L. Lagneaux, "Mesenchymal stromal cells and toll-like receptor priming : a critical review," *Immune Network*, vol. 17, no. 2, pp. 89–102, 2017.
- [42] C. A. Janeway and R. Medzhitov, "INNATEIMMUNERE-COGNITION," Annual Review of Immunology, vol. 20, no. 1, pp. 197–216, 2002.
- [43] C. Ries, V. Egea, M. Karow, H. Kolb, M. Jochum, and P. Neth, "MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells : differential regulation by inflammatory cytokines," *Blood*, vol. 109, no. 9, pp. 4055–4063, 2007.